Navigation Links
Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
Date:4/27/2009

COPENHAGEN, April 27 /PRNewswire/ -- As a testimony to the strength of Santaris Pharma's efficient Drug Discovery Engine, the Company announced today the completion of the delivery of six cancer target drug candidates to their collaboration partner Enzon Pharmaceuticals. All six drug candidates have been designed, synthesized and selected in collaboration with Enzon, within 24 months of commencing the collaboration.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090420/344344 )

"Our collaboration with Enzon Pharmaceuticals has been very productive and goal oriented enabling both companies to benefit optimally from our ability to rationally design, discover and select potent and safe RNA targeted drugs within a short time span," said Henrik 0rum, Santaris Pharma's Chief Scientific Officer.

Santaris Pharma and Enzon Pharmaceuticals signed their agreement in 2006. As part of the agreement Santaris Pharma retains the lucrative commercial rights to the drugs within Europe. The agreement included two LNA based RNA inhibitors at the pre-clinical stage, EZN2968 against HIF-1ÿ±, and EZN3042 against Survivin, both of which are currently in Phase I studies conducted by Enzon, and the development of six additional cancer target drugs selected by Enzon which are in various stages of preclinical development.

"We are encouraged by the data generated by the first two lead candidates," said Dr. Ivan Horak, Executive Vice President of Research, Development and Chief Scientific Officer, Enzon Pharmaceuticals. "In addition, I'm pleased to see the continued validation of the Locked Nucleic Acid (LNA) technology as we continue to evaluate the additional targets in preclinical programs."

http://www.santaris.com

Santaris Pharma (founded in 2003)
'/>"/>

SOURCE Santaris Pharma A/S
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
2. Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
3. China Biologic Products Receives $5.3 Million Order from Largest Biopharmaceutical Distributor in India
4. Xspray Expands to Meet Pharmas Interest in its Ground-Breaking Particle Production Technology
5. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar
6. Sinobiopharma Reports a 141% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
7. Sinobiopharma Reports a 41% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
8. Helix BioPharma to Present at the BioFinance 2009 Conference
9. Merck Engages PharmaVentures to Assist in the Divestment of its Italian Research Centre IRBM
10. Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
11. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... May 21, 2013 Vital Imaging ... University of California, San Diego for a joint study ... Gravitic™ MRI (Magnetic Resonance Imaging) with that of a ... its continued pursuit of improved healthcare by combining cutting ... is an extremely valuable tool for evaluating pathological changes ...
(Date:5/21/2013)... CA (PRWEB) May 21, 2013 Clinovo's ... is an 8-week training program starting on June 11th, ... help clinical trial professionals reach the next step in ... Dentons Offices in Palo Alto, and streamed online. , ... of award-winning papers, Clinovo's new “CDISC Standards: Theory and ...
(Date:5/20/2013)... 20, 2013 Today, at the American Psychiatric ... , James McGough , M.D., M.S., ... Semel Institute for Neuroscience and Human Behavior and ... the University of California Los Angeles (UCLA), and director ... Psychopharmacology and ADHD at UCLA, presented the results of ...
(Date:5/20/2013)... ROCKVILLE , Md. and BALTIMORE ... Inc. (BHI), a regional private-public partnership focusing ... to early-stage funding in Central Maryland ... Aiyar, Ph.D., M.B.A., as the first Entrepreneur-in-Residence (EIR) ... (NIH) National Heart, Lung and Blood Institute ...
Breaking Biology Technology:Vital Imaging Makes Greater Commitment into MRI Research 2Vital Imaging Makes Greater Commitment into MRI Research 3Clinovo Launches TechTrainings on CDISC Standards 2Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 2Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 3Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 4Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 5BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 2BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 3BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 4
... - iCo Therapeutics Inc. (TSX-V: ICO) is pleased to ... This financing provides the company with sufficient capital to ... 1 clinical trial. iCo-007 is targeting the treatment of ... the company with additional working capital. iCo,s partner Isis ...
... Inc. (Nasdaq: VRUS ), a clinical ... commercializing novel drugs to treat viral infections, reported ... quarter ended December 31, 2008. Financial Results ... quarters ended December 31, 2008 and December 31, ...
... 9 Celsis In Vitro Technologies (Celsis,IVT), a ... science,products and laboratory services company, and Wisconsin-based Promega ... ADME-Tox testing in primary,hepatocytes. Celsis IVT is ... with Promega,s bioluminescent ADME-Tox assays, including,the P450-Glo(TM) CYP ...
Cached Biology Technology:iCo Therapeutics Closes $1.3 Million Private Placement 2iCo Therapeutics Closes $1.3 Million Private Placement 3Pharmasset Reports Fiscal First Quarter 2009 Financial Results 2Pharmasset Reports Fiscal First Quarter 2009 Financial Results 3Pharmasset Reports Fiscal First Quarter 2009 Financial Results 4Pharmasset Reports Fiscal First Quarter 2009 Financial Results 5Pharmasset Reports Fiscal First Quarter 2009 Financial Results 6Pharmasset Reports Fiscal First Quarter 2009 Financial Results 7Pharmasset Reports Fiscal First Quarter 2009 Financial Results 8Celsis In Vitro Technologies and Promega to Offer Fast, Reliable Solutions for ADME-Tox Testing With Primary Hepatocytes 2Celsis In Vitro Technologies and Promega to Offer Fast, Reliable Solutions for ADME-Tox Testing With Primary Hepatocytes 3
(Date:5/21/2013)... of Michigan Water Center today awarded 12 research ... restoration and protection efforts. , The two-year grants ... including efforts to track the remediation of harmful ... control non-native weedy plant invasions; study chromosomal damage ... to restoration activities. , The grants were awarded ...
(Date:5/21/2013)... the past few decades, scientists have developed many devices ... metallic stents. While generally effective, each of these treatments ... A new study from MIT analyzes the potential usefulness ... angioplasty balloons and drug-releasing stents, but may pose fewer ... in the artery for only a brief period, during ...
(Date:5/20/2013)... are also commonly resistant to antimicrobial substances made ... in mBio , the online open-access journal ... colistin and host antimicrobials LL-37 and lysozyme, which ... mean that patients with life-threatening multi-drug resistant infections ... Colistin is a last-line drug for treating several ...
Breaking Biology News(10 mins):U-M Water Center awards $570K in Great Lakes restoration grants 2U-M Water Center awards $570K in Great Lakes restoration grants 3U-M Water Center awards $570K in Great Lakes restoration grants 4Evaluating a new way to open clogged arteries 2Evaluating a new way to open clogged arteries 3Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3
... 2011Mary Ann Liebert, Inc., publishers ( http://www.liebertpub.com ) ... Technology , a highly innovative, bimonthly peer-reviewed journal ... the potential to significantly improve human health, well-being, ... innovative results, essential data, cutting-edge discoveries, thorough syntheses ...
... November 14, 2011 The possibility that functional, three-dimensional ... such as embryonic stem cells (ESCs) and induced pluripotent ... of stem cell research, but is also one of ... medicine. Developmental biology has played a central role in ...
... University Hospitals Case Medical Center researchers could still be ... not as they originally thought. LateTIME was a ... marrow that were believed to have the ability to ... the heart within two weeks of the attack. Results ...
Cached Biology News:New journal on disruptive science and technology launching in 2012 2Self-organized pituitary-like tissue from mouse ES cells 2Self-organized pituitary-like tissue from mouse ES cells 3Self-organized pituitary-like tissue from mouse ES cells 4Post heart attack recovery may not be aided by stem cell injections, but trial demonstrates promise 2
... for easy storage. Linkage: This CLS number is ... Cornings product number. If showing no availability yet, ... or contact customer service for assistance. ID clarifier: ... 55 cm 2 D H 100 ...
... Mixes are formulated for use in one-step ... Green. One-step QRT-PCR mixes offer a quick ... pipetting steps are minimised, making the protocol ... 2x ABsolute QRT-PCR Mix is supplied with ...
... wide variety of environmental and pathophysiological stressful ... of proteins known as heat shock proteins ... proteins (SRPs). The Hsp90 family of ... alpha and beta, Grp94, and Trap-1 (Hsp75). ...
... offers bespoke, cost-effective solutions for complex protein processing and ... and experience to help you develop a solution to ... , ... transfer all methodology to your ...
Biology Products: